Orthomyxoviridae

Orthomyxoviridae
Name	Orthomyxoviridae
Virus group	RNA viruses
Family	Orthomyxoviridae
Genera	Influenzavirus A; Influenzavirus B; Influenzavirus C; Influenzavirus D; Thogotovirus; Isavirus; Quaranjavirus

Orthomyxoviridae Orthomyxoviridae is a family of negative-sense, segmented RNA viruses that includes the influenza viruses responsible for seasonal epidemics and occasional pandemics. First characterized in the 20th century, members of this family have shaped public health responses associated with influenza outbreaks, influenced policies in nations such as the United States and United Kingdom, and prompted international coordination by organizations like the World Health Organization and Centers for Disease Control and Prevention. Research into Orthomyxoviridae has involved laboratories and institutions including the Rockefeller University, National Institutes of Health, Pasteur Institute, and industrial partners such as GlaxoSmithKline and Pfizer.

Taxonomy and Classification

The family Orthomyxoviridae comprises several genera recognized by taxonomic authorities such as the International Committee on Taxonomy of Viruses and has been revised alongside guidance from agencies like the European Centre for Disease Prevention and Control and the World Organisation for Animal Health. Influenzavirus A, Influenzavirus B, Influenzavirus C, Influenzavirus D, Thogotovirus, Isavirus, and Quaranjavirus are the principal genera; Influenzavirus A is subdivided into subtypes by hemagglutinin and neuraminidase variants, the naming conventions of which were central during the 1918 influenza pandemic, the 1957 influenza pandemic, the 1968 influenza pandemic, and the 2009 swine flu pandemic. Classification incorporates genomic segmentation profiles, antigenic properties, and host associations, paralleling practices used by taxonomists at institutions like the Smithsonian Institution and research consortia at the University of Oxford.

Structure and Genome

Orthomyxoviridae virions are enveloped, pleomorphic particles studded with surface glycoproteins, a morphology analyzed in structural studies conducted at facilities such as the Max Planck Society and Cold Spring Harbor Laboratory. The negative-sense RNA genome is segmented—typically eight segments in Influenzavirus A and B—allowing reassortment, a mechanism implicated in major antigenic shifts recorded during events involving public figures and policymaking bodies including the League of Nations (historical health debates) and modern forums like the G7. Key proteins include hemagglutinin (HA) and neuraminidase (NA), along with matrix (M1), ion channel (M2), nucleoprotein (NP), and polymerase complex subunits (PB1, PB2, PA), all subjects of molecular investigations at centers including the Wellcome Trust and Harvard University. Comparative genomics linking viral segments to host adaptation has been pursued in collaborations with the Scripps Research Institute and the Karolinska Institute.

Replication Cycle and Pathogenesis

Entry begins with HA-mediated attachment to sialic acid receptors on host cells, a process compared in mechanistic studies alongside receptor analyses performed at institutions such as the Massachusetts Institute of Technology and Johns Hopkins University. After endocytosis and membrane fusion mediated by low pH in endosomes, the viral ribonucleoprotein complexes are imported to the nucleus—a distinguishing feature noted in virology texts from publishers like Oxford University Press—where transcription and replication occur using the viral RNA-dependent RNA polymerase. Antigenic drift via point mutations and antigenic shift via reassortment, processes monitored by surveillance networks involving the WHO Global Influenza Surveillance and Response System and national labs such as the Public Health Agency of Canada, drive pathogenesis and immune escape. Host immune responses involving cytokine signaling have been profiled in studies linked to laboratories at the Karolinska Institute and Imperial College London.

Host Range and Transmission

Orthomyxoviridae infect a wide host range: Influenzavirus A infects birds, humans, swine, horses, and marine mammals, with avian reservoirs such as those studied at the Cornell Lab of Ornithology and agricultural implications examined by the Food and Agriculture Organization; Influenzavirus B primarily infects humans and seals; C and D have narrower host spectra involving humans and livestock. Transmission modes include respiratory droplets, direct contact, and fomites, scenarios evaluated in outbreak investigations by agencies such as the European Centre for Disease Prevention and Control and field studies funded by organizations like the Bill & Melinda Gates Foundation. Zoonotic spillover events linking wildlife, livestock, and human interfaces have been focal points in One Health initiatives supported by the World Health Organization and the United Nations.

Clinical Manifestations and Epidemiology

Clinical presentations range from mild upper respiratory illness to severe pneumonia and systemic complications, clinical management guided by protocols from the World Health Organization, Centers for Disease Control and Prevention, and regional health ministries such as the Ministry of Health (Brazil). Influenza-associated morbidity and mortality have influenced public health policy in nations including Japan and Australia, and epidemiologic patterns are tracked seasonally across temperate and tropical regions through collaborations with national influenza centers and academic hubs like the University of Melbourne and Peking University. High-risk groups identified by health authorities include the elderly, pregnant persons, and immunocompromised patients, with outcomes monitored in longitudinal studies by institutions such as the Framingham Heart Study infrastructure and global burden analyses published in outlets associated with the Lancet.

Prevention, Treatment, and Control

Prevention relies on vaccination campaigns coordinated by the World Health Organization seasonal recommendations and implemented by national programs in countries like the United States and Canada using vaccine strains selected by international experts from bodies including the Vaccine Research Center. Antiviral therapeutics—neuraminidase inhibitors and polymerase inhibitors—have been developed and distributed by pharmaceutical companies such as Roche and Gilead Sciences and evaluated in clinical trials overseen by regulatory authorities like the European Medicines Agency and the Food and Drug Administration. Nonpharmaceutical interventions, surveillance, and pandemic preparedness plans involve multilateral cooperation among entities including the United Nations, the World Bank, and regional public health agencies. Ongoing research on universal vaccines, monoclonal antibodies, and next-generation antivirals is conducted at research centers such as the National Institutes of Health, Broad Institute, and university laboratories worldwide.

Category:Viruses